How to Help Your Patients Find Clozapine in Stock: A Provider's Guide

Your Patient Can't Find Clozapine — Now What?

You've done the hard work of identifying a patient with treatment-resistant schizophrenia, navigating the clinical decision to start Clozapine, and building a monitoring protocol. Then you get the call: "My pharmacy doesn't have it."

Despite the FDA's removal of the Clozapine REMS program in June 2025, many patients still struggle to find a pharmacy that stocks this medication. The good news is that the situation is improving — but in the meantime, your clinical team can play a critical role in helping patients maintain access to the one medication that's working for them.

This guide outlines five practical steps providers can take, plus alternatives and workflow strategies to minimize disruptions.

Current Availability: Where Things Stand

As of early 2026:

• Clozapine is not in shortage. The FDA's drug shortage database does not list Clozapine, and generic tablets are being manufactured by multiple companies.
• The access problem is pharmacy-level. Many pharmacies — particularly chain locations — don't stock Clozapine because they either haven't updated their ordering practices post-REMS or see insufficient local demand.
• Specialty formulations are scarcer. Orally disintegrating tablets (FazaClo) and oral suspension (Versacloz) have fewer manufacturers and less widespread availability.
• Rural and underserved areas are disproportionately affected. Pharmacies in these areas may have even less incentive to stock a low-volume specialty medication.

For the full regulatory and market context, see our provider briefing on Clozapine access in 2026.

Why Patients Can't Find Clozapine

Understanding the barriers helps you address them more effectively:

• Legacy REMS hesitancy: Some pharmacies still believe they need certification to dispense Clozapine. Pharmacy staff may not be aware the REMS was removed.
• Low demand perception: With relatively few patients per pharmacy, some locations don't stock it because they see it as a rarely requested item.
• Ordering inertia: Pharmacies that never stocked Clozapine during the REMS era haven't added it to their automated ordering systems.
• ANC coordination concerns: Without the REMS system, some pharmacists are unsure about their role in verifying ANC results.

5 Steps Providers Can Take

Step 1: Establish Relationships With Clozapine-Stocking Pharmacies

Identify 2-3 pharmacies in your area that reliably stock Clozapine. These are most likely:

• Hospital outpatient pharmacies
• Independent pharmacies that serve psychiatric practices
• Specialty pharmacies focused on mental health medications

Maintain a list and share it with your patients. Update it periodically as availability changes.

Step 2: Use Medfinder to Check Real-Time Availability

Medfinder's provider tools let you search for pharmacy availability by medication and location. When a patient calls saying they can't find their Clozapine, your front desk or care coordinator can search Medfinder and provide pharmacy options in real time.

Consider bookmarking medfinder.com/providers on your staff's workstations.

Step 3: Proactively Educate Pharmacies

If a patient's preferred pharmacy refuses or hesitates to stock Clozapine, a brief call from your office can make a difference. Key points to communicate:

• The Clozapine REMS was removed by the FDA effective June 13, 2025
• No pharmacy certification is required to order, stock, or dispense Clozapine
• Wholesalers can ship Clozapine to any licensed pharmacy
• ANC monitoring remains a clinical responsibility between the prescriber and patient — the pharmacy does not need to verify ANC
• Direct the pharmacy to the FDA's REMS removal announcement for reference

Step 4: Consider Formulation Flexibility

If standard tablets aren't available, check whether an alternative formulation is in stock:

• Standard tablets: 25 mg, 50 mg, 100 mg, 200 mg (most widely available)
• Orally disintegrating tablets (FazaClo): 12.5 mg, 25 mg, 100 mg, 150 mg, 200 mg
• Oral suspension (Versacloz): 50 mg/mL

Writing for an alternative formulation may solve an immediate access problem, though note that ODT and suspension tend to be pricier.

Step 5: Integrate Pharmacy Checks Into Your Workflow

Build pharmacy verification into your clinic's refill process. When patients are due for a refill:

1. Confirm ANC results are current
2. Check with the patient's pharmacy (or have them check Medfinder) that Clozapine is in stock
3. Send the prescription once availability is confirmed
4. If the pharmacy doesn't have it, identify an alternative location before the patient runs out

This proactive approach prevents the crisis scenario where a patient discovers their pharmacy is out of stock with only 1-2 days of medication left.

Alternatives If Access Remains Problematic

If a specific patient consistently struggles with Clozapine access despite these measures, consider:

• Augmentation strategies: Adding Risperidone, Amisulpride, or Lamotrigine to a lower dose of Clozapine (may reduce the required supply)
• Switching to a more available antipsychotic: Olanzapine has the most evidence as an alternative in TRS, though no drug matches Clozapine's proven efficacy
• Mail-order specialty pharmacy: Some specialty pharmacies offer mail-order services for Clozapine with built-in ANC coordination

For a patient-facing resource on alternatives, see alternatives to Clozapine.

Workflow Tips for Your Practice

• Designate a Clozapine coordinator — one staff member who tracks all Clozapine patients' refill cycles, ANC results, and pharmacy availability
• Build a pharmacy reference list — keep an updated list of Clozapine-stocking pharmacies in your area
• Set calendar reminders — for each Clozapine patient, set reminders 10 days before expected refill date
• Communicate the REMS removal — share the FDA announcement with your local pharmacy network; many pharmacists may not be aware of the change
• Leverage Medfinder — use medfinder.com/providers as part of your standard workflow for checking medication availability

Final Thoughts

Clozapine access is a solvable problem — it just requires a bit of extra effort during this transition period. By establishing pharmacy relationships, leveraging availability tools like Medfinder, and building proactive workflows, your practice can help ensure that patients who depend on Clozapine don't experience dangerous interruptions in their treatment.

The REMS removal is a step in the right direction. Providers who help pharmacies understand the new landscape can accelerate the improvement in access for all Clozapine patients.

For the broader regulatory context, read our Clozapine shortage briefing for providers. For cost-saving resources to share with patients, see how to help patients save money on Clozapine.